Denosumab(Others approved) bulk supplier for pharma manufacturers

Denosumab(Others Approved) 60 mg, 120 mg Suppliers & Bulk Manufacturers

Available Forms: Subcutaneous injection

Available Strengths: 60 mg, 120 mg

Reference Brands: Xgeva (US & EU)

Biosimilars of Xgeva (denosumab) inhibit RANKL, preventing osteoclast formation and activity. They reduce bone destruction, fractures, and skeletal-related events in cancer and osteoporosis patients. Benefits include similar efficacy, lower costs, increased treatment access, and support for patient bone health when used under medical supervision.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Denosumab(Others Approved)? List it or send an offer →

Product Description:

Biosimilars of Xgeva (denosumab) are regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involves extensive comparison, clinical validation, and safety data. In the EU, CE marking certifies conformity under the MDR. These biosimilars undergo validation, stability testing, and audits, supported by comprehensive documentation including biosimilarity, clinical trial data, safety profiles, and manufacturing practices. Ensuring compliance guarantees access to affordable, high-quality denosumab biosimilars, supporting osteoporosis and bone metastasis treatment worldwide.

Denosumab(Others Approved) — third party manufacturing & bulk supply

Denosumab(Others Approved) 60 mg, 120 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Denosumab(Others Approved) is supplied as Subcutaneous injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Denosumab(Others Approved) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Denosumab(Others Approved) →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Denosumab(Others approved) is listed as Subcutaneous injection in 60 mg, 120 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Denosumab(Others approved) is referenced against Xgeva (US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.